Project Grant R21NS145499
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded the Regents of the University of Michigan a $633,146 Project Grant effective August 4, 2025, through July 31, 2030, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). This research initiative addresses the identification of modifiable factors associated with vascular cognitive impairment and dementia (VCID) occurring after stroke, a...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded Massachusetts General Hospital $653,192 on July 18, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to conduct a longitudinal in vivo imaging study investigating pathological fibrin deposition in the human brain and its relationship to progressive neurodegeneration in multiple sclerosis (MS). The research employs a...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $234,630 to Massachusetts General Hospital (MGH) on August 1, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The five-year project, concluding July 31, 2030, focuses on promoting recovery from brain injury through investigation of non-invasive thalamic Low-Intensity Focused Ultrasound Pulsation (LIFUP). The research...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded Massachusetts General Hospital $628,373 under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program on August 1, 2025, for a five-year project period extending through June 30, 2030. This Project Grant supports fundamental and translational research focused on understanding the immunobiology of conventional dendritic cells (CDC1) and their...
- Federal Project Grant Award Summary Baylor College of Medicine received a $149,766 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective September 6, 2026 through January 6, 2029. This award supports research investigating the role of the SLC4A4 gene in vascular dementia (VAD), the second most common subtype of dementia. The research...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded Massachusetts General Hospital a Project Grant of $511,402 effective February 1, 2026, through January 31, 2031, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award supports translational research to develop and validate non-invasive transcutaneous vagus nerve stimulation (NVNS) as a novel neuromodulatory therapeutic...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded Boston University Medical Campus a Project Grant of $649,800 on May 7, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The research will be conducted through February 28, 2031, at the institution's Roxbury, Massachusetts facility. This award funds a comprehensive investigation into the impact of social isolation, loneliness,...
- Federal Project Grant Award Summary Tufts Medical Center Parent, Inc. (doing business as Tufts Medical Center) received a $616,031 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award, obligated on May 5, 2026, funds research through February 28, 2031, and supports fundamental and translational neuroscience research investigating the role...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a Project Grant totaling $165,512 to Indiana University Indianapolis, effective June 1, 2026, through October 8, 2029, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853). This award supports investigative research examining platelet-mediated mechanisms of vascular injury in mouse models of vascular contributions to cognitive impairment and...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded Massachusetts Institute of Technology a $248,266 Project Grant effective July 1, 2025, through June 30, 2027, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). This award supports the development of a novel magnetic resonance imaging (MRI) method to concurrently measure hemodynamics, brain tissue displacement, and...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded The General Hospital Corporation (Massachusetts General Hospital) a $439,150 Project Grant effective June 1, 2026 through May 31, 2028 under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). This research project investigates exercise preconditioning and compensatory oligodendrogenesis in subcortical ischemic vascular dementia (SIVD), focusing on understanding how oligodendrocyte precursor cells (OPCs) proliferate and differentiate to repair white matter damage following ischemic injury. The research addresses a critical gap in knowledge regarding the cellular and molecular mechanisms governing OPC regulation in the adult brain under pathological conditions, with particular emphasis on exploring exercise as a non-pharmacological therapeutic approach to mitigate cognitive decline in dementia patients. The grant supports fundamental and translational research to elucidate white matter damage and repair processes in vascular contributions to cognitive impairment and dementia (VCID), the most common subtype of which is SIVD. As the global population ages, incidence of SIVD is expected to increase, making this research relevant to developing effective treatments and reducing polypharmacy-related complications in elderly patients. Research will be conducted at MGH's facility in Charlestown, Massachusetts, leveraging the institution's substantial biomedical research infrastructure and expertise in neuroscience translational research.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $439.2k | 5/12/26 |